title: [Microbial metabolites that inhibit sterol biosynthesis, their chemical diversity and characteristics of mode of action].
abstract: Inhibitors of sterol biosynthesis (ISB) are widespread in nature and characterized by appreciable diversity both in their chemical structure and mode of action. Many of these inhibitors express noticeable biological activity and approved themselves in development of various pharmaceuticals. In this review there is a detailed description of biologically active microbial metabolites with revealed chemical structure that have ability to inhibit sterol biosynthesis. Inhibitors of mevalonate pathway in fungous and mammalian cells, exhibiting hypolipidemic or antifungal activity, as well as inhibitors of alternative non-mevalonate (pyruvate gliceraldehyde phosphate) isoprenoid pathway, which are promising in the development of affective antimicrobial or antiparasitic drugs, are under consideration in this review. Chemical formulas of the main natural inhibitors and their semi-synthetic derivatives are represented. Mechanism of their action at cellular and biochemical level is discussed. Special attention is given to inhibitors of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase (group of lovastatin) and inhibitors of acyl-CoA-cholesterol-acyl transferase (ACAT) that possess hypolipidemic activity and could be affective in the treatment of atherosclerosis. In case of inhibitors of late stages of sterol biosynthesis (after squalene formation) special attention is paid to compounds possessing evident antifungal and antitumoral activity. Explanation of mechanism of anticancer and antiviral action of microbial ISB, as well as the description of their ability to induce apoptosis is given.
authors.forename: A S
authors.initials: AS
authors.lastname: Trenin
mesh_terms: D000101:Acetyl-CoA C-Acetyltransferase / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism; D000214:Acyl Coenzyme A / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D008148:Lovastatin / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D053858:Metabolic Networks and Pathways; D008798:Mevalonic Acid / Q000378:metabolism; D013185:Squalene / Q000737:chemistry / Q000378:metabolism; D013261:Sterols / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism*
chemical_list: D000214:Acyl Coenzyme A; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013261:Sterols; C008047:3-hydroxy-3-methylglutaryl-coenzyme A; D013185:Squalene; D008148:Lovastatin; C506639:ACAT1 protein, human; D000101:Acetyl-CoA C-Acetyltransferase; D008798:Mevalonic Acid